Evidence map›Paper›PMID 42126328›Full record

ArticleBritish journal of clinical pharmacology2026

Time to accelerate rare disease research: AI-powered in silico trials, digital twin-driven RCTs and decision-grade real-world evidence.

Andrej Belančić, Elvira Meni Maria Gkrinia, Oscar Della Pasqua, Reecha Sofat, Dinko Vitezić, Robert Likić

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrej BelančićDepartment of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.ORCID https://orcid.org/0000-0001-7848-6600
Elvira Meni Maria GkriniaIndependent Researcher, Athens, Greece.ORCID https://orcid.org/0009-0002-1255-8653
Oscar Della PasquaClinical Pharmacology & Therapeutics Group, University College London, London, UK.ORCID https://orcid.org/0000-0002-6211-1430
Reecha SofatDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID https://orcid.org/0000-0002-0242-6115
Dinko VitezićDepartment of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
Robert LikićDepartment of Internal Medicine, School of Medicine, University of Zagreb, Zagreb, Croatia.ORCID https://orcid.org/0000-0003-1413-4862

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical trialsdigital twinsin silico trialsrare diseasesreal‐world evidence

Identifiers

PMID42126328
PMCPMC13304242

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.